Pascal Besman, COO Pharmamar – PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in the USA. Pascal Besman, Pharmamar COO discusses advantages and potential limitations of the new drug.
Pascal Besman, COO Pharmamar – PharmaMar to submit New Drug Application (NDA) for lurbinectedin
By Editor